Ann: Notice of Annual General Meeting/Proxy Form, page-14

Another table comparing the remuneration of our Chairman and previous CEO against peers.

I mentioned this before but if Kate is taking his previous day-to-day CEO duties, would it be reflected in his remuneration.

I do, however, acknowledged his increased oversight for the enlarged group.

	Column 1	Column 2	Column 3	Column 4	Column 5
0	Company	Market cap ($million)	Position	Base salary and fees	12 month share price change
1	Alcidion group	37.9	Ray Blight (Executive Chairman)	$261,613	-9%
2	Volpara Health	162.1	Dr Ralph Highnam (Executive Director)	$280,305	+71%
3	Impedimed	170.5	Richard Carreon (Managing Director and CEO)	$646,690	-42%
4	LBT Innovations	23.1	Brent Barnes (Managing Director and CEO)	$237,000	-64%
5	Capitol Health	233.7	Andrew Demetriou (Chairman and Non-Executive Director)	$254,160	+5%
6	Capitol Health	233.7	Andrew Harrison (Managing Director and CEO)	$633,076	+5%
7	Medadvisor	52.9	Robert Read (CEO)	$270,474	+11%